SPE Capital & Proparco’s acquisition of Amanys Pharma’s operations in Sub-Saharan Africa

Lead party: SPE Capital Partners (investor/buyer)Coverage: Meridian Capital (investment and transaction tracker; data from Partner Researchers, editorially reviewed). Target: Amanys Pharma (private company) · Sector: Healthcare, Pharmaceuticals · Countries of operation: Morocco Transaction type: Investment · Asset class: Private Equity · Strategy: Buyout · Instrument: Equity · Equity stake: 1% · Fund: SPE Africa Industrialisation…


Lead party: SPE Capital Partners (investor/buyer)

Coverage: Meridian Capital (investment and transaction tracker; data from Partner Researchers, editorially reviewed).

Target: Amanys Pharma (private company) · Sector: Healthcare, Pharmaceuticals · Countries of operation: Morocco

Transaction type: Investment · Asset class: Private Equity · Strategy: Buyout · Instrument: Equity · Equity stake: 1% · Fund: SPE Africa Industrialisation Fund I

Investors/buyers: SPE Capital Partners, Proparco

Legal advisers: not identified in the source record.

Source: announced 1 April 2020. Original announcement: spe-capital.com.